These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1318 related articles for article (PubMed ID: 19157995)
1. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden. Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A; J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995 [TBL] [Abstract][Full Text] [Related]
2. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. Hansen CR; Pressler T; Høiby N J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078 [TBL] [Abstract][Full Text] [Related]
3. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Emerson J; McNamara S; Buccat AM; Worrell K; Burns JL Pediatr Pulmonol; 2010 Apr; 45(4):363-70. PubMed ID: 20232473 [TBL] [Abstract][Full Text] [Related]
4. Changes in lung function in young cystic fibrosis patients between two courses of intravenous antibiotics against Pseudomonas aeruginosa. Béghin L; Michaud L; Loeuille GA; Wizla-Derambure N; Sayah H; Sardet A; Thumerelle C; Deschildre A; Turck D; Gottrand F Pediatr Pulmonol; 2009 May; 44(5):464-71. PubMed ID: 19360849 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods. Pressler T; Karpati F; Granström M; Knudsen PK; Lindblad A; Hjelte L; Olesen HV; Meyer P; Høiby N; J Cyst Fibros; 2009 Jan; 8(1):37-42. PubMed ID: 18835753 [TBL] [Abstract][Full Text] [Related]
6. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study. Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM; J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537 [TBL] [Abstract][Full Text] [Related]
7. Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population. Bradbury R; Champion A; Reid DW Respirology; 2008 Nov; 13(6):886-92. PubMed ID: 18811887 [TBL] [Abstract][Full Text] [Related]
8. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. Hansen CR; Pressler T; Koch C; Høiby N J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679 [TBL] [Abstract][Full Text] [Related]
9. Pulmonary infection in mild variant cystic fibrosis: implications for care. Lording A; McGaw J; Dalton A; Beal G; Everard M; Taylor CJ J Cyst Fibros; 2006 May; 5(2):101-4. PubMed ID: 16426904 [TBL] [Abstract][Full Text] [Related]
10. Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis. Lebecque P; Leal T; Zylberberg K; Reychler G; Bossuyt X; Godding V J Cyst Fibros; 2006 Dec; 5(4):237-44. PubMed ID: 16790367 [TBL] [Abstract][Full Text] [Related]
11. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Greally P; Whitaker P; Peckham D Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602 [TBL] [Abstract][Full Text] [Related]
12. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. De Baets F; Schelstraete P; Van Daele S; Haerynck F; Vaneechoutte M J Cyst Fibros; 2007 Jan; 6(1):75-8. PubMed ID: 16793350 [TBL] [Abstract][Full Text] [Related]
13. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. Hansen CR; Pressler T; Hoiby N; Johansen HK J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202 [TBL] [Abstract][Full Text] [Related]
14. Clinical profile of adult cystic fibrosis patients with frequent epidemic clones of Pseudomonas aeruginosa. Tingpej P; Elkins M; Rose B; Hu H; Moriarty C; Manos J; Barras B; Bye P; Harbour C Respirology; 2010 Aug; 15(6):923-9. PubMed ID: 20573059 [TBL] [Abstract][Full Text] [Related]
15. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641 [TBL] [Abstract][Full Text] [Related]
16. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. Proesmans M; Vermeulen F; Boulanger L; Verhaegen J; De Boeck K J Cyst Fibros; 2013 Jan; 12(1):29-34. PubMed ID: 22762867 [TBL] [Abstract][Full Text] [Related]
17. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response. Ciofu O APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154 [TBL] [Abstract][Full Text] [Related]
18. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142 [TBL] [Abstract][Full Text] [Related]
19. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Ratjen F; Munck A; Kho P; Angyalosi G; Thorax; 2010 Apr; 65(4):286-91. PubMed ID: 19996339 [TBL] [Abstract][Full Text] [Related]
20. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Tramper-Stranders GA; Wolfs TF; van Haren Noman S; van Aalderen WM; Nagelkerke AF; Nuijsink M; Kimpen JL; van der Ent CK Thorax; 2010 Oct; 65(10):915-20. PubMed ID: 20729233 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]